跳至主要内容
临床试验/NCT02117557
NCT02117557Unknown2 期

A Prospective Randomized Controlled Trial Comparing Transumbilical Single Incision Versus Conventional Laparoscopic Surgery for Colorectal Cancer

Guoxin Li1 个研究点 分布在 1 个国家目标入组 198 人开始时间: 2014年4月最近更新:
适应症

试验速览

阶段
2 期
发起方
入组人数
198
试验地点
1
主要终点
Early morbidity rate

研究概览

简要总结

  • Compared with traditional open colectomy, laparoscopic surgery is associated with less pain, earlier recovery, and better cosmetic outcome, and its short- and long-term oncologic outcomes have been demonstrated.
  • In experienced surgeons' hands, single incision laparoscopic surgery is increasingly performed for colorectal disease, and even for malignant lesion because of its reduced incision-associated morbidity and scarring.
  • However, the safety and efficacy of single incision laparoscopic surgery for colorectal cancer has not yet been evaluated. Thus, the prospective randomized trial comparing single incision versus conventional laparoscopic surgery for colorectal cancer is needed.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 18 years < age < 80 years
  • Tumor located in rectosigmoid (defined as 10- to 30-cm from the anal verge)
  • Pathological rectosigmoid carcinoma
  • Preoperative T stage ranging from T1 to T4a according to the 7th Edition of AJCC Cancer Staging Manual
  • Tumor size of 5 cm or less; 6) ECOG score is 0-1
  • ASA socre is Ⅰ-Ⅲ
  • Informed consent

排除标准

  • Body mass index (BMI) >30 kg/m2
  • Pregnant woman or lactating woman
  • Severe mental disease
  • Previous abdominal surgery
  • Emergency operation due to complication (bleeding, perforation or obstruction) caused by colorectal cancer
  • Requirement of simultaneous surgery for other disease

结局指标

主要结局

Early morbidity rate

时间窗: 30 days

The early morbidity rate is defined as the event observed during operation and within 30 days after surgery,

次要结局

  • Operative outcomes(intraoperative)
  • Pathological outecomes(5 days)
  • Postoperative recovery course(14 days)
  • Pain score(14 days)
  • Cosmetic assessment(14 days)
  • 3-year disease free survival rate(36 months)
  • 5-year overall survival rate(60 months)
  • Inflammatory and immune response(7 days)

研究者

发起方
Guoxin Li
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Guoxin Li

M.D., Ph.D.

Nanfang Hospital, Southern Medical University

研究点 (1)

Loading locations...

相似试验